CoChat
Sign Up
Cited by 31Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes

Open access
Onishi, Yukiko, Oura, Tomonori, Nishiyama, Hiroshi, Ohyama, Sumika, Takeuchi, Masakazu, Iwamoto, Noriyuki·2016·Endocrine Journal
DOI 10.1507/endocrj.ej15-0518
Open this paper in CoChat — free accountOpen PDF

Abstract

The efficacy and tolerability of once weekly dulaglutide 0.75 mg in Japanese patients with type 2 diabetes (T2D) were evaluated by subgroups defined by key demographic characteristics. This post hoc analysis included data from patients who received dulaglutide 0.75 mg for up to 26 weeks in three phase 3 trials (one open-label, randomized; one double-blind and open-label, randomized; one open-label, nonrandomized). Patients were classified into subgroups on the basis of sex (male, female), age (<65, ≥65 years), body weight (<70, ≥70 kg), body mass index (BMI; <25, ≥25 kg/m(2)), duration of diabetes (<7, ≥7 years), HbA1c (≤8.5, >8.5%), use of concomitant sulfonylurea (yes, no), and use of concomitant biguanide (yes, no). Efficacy measures analyzed were changes from baseline in HbA1c and body weight and percentages of patients achieving HbA1c <7.0%. Safety measures analyzed were incidence of hypoglycemia and nausea and change from baseline in seated pulse rate. A total of 855 patients were analyzed. Once weekly dulaglutide 0.75 mg improved blood glucose control as measured by HbA1c regardless of patient characteristics; patients with higher baseline HbA1c values had greater improvements compared to patients with lower baseline values. Weight loss was greater in patients with lower baseline HbA1c and in patients taking concomitant biguanides. Concomitant use of sulfonylureas had the greatest effect on the incidence of hypoglycemia. Treatment of T2D with once weekly dulaglutide 0.75 mg for 26 weeks was associated with significant improvement in glycemic control irrespective of age, sex, duration of diabetes, body weight, BMI, or concomitant medication.

Overview

Integrity signals

Registry

Crossref · 10.1507/endocrj.ej15-0518

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. 18. Pharmaceuticals and Medical Devices Agency (2014) Review report for new indication of liraglutide (Victoza). Available at http://www.pmda.go.jp/drugs/2014/P201400122/620023000_22200AMX00236_A100_1.pdf (In Japanese). Accessed 10 August 2015.

Cited by

Sorted by citations

Related

Metadata

Authors
Onishi, Y., Oura, T., Nishiyama, H., Ohyama, S., Takeuchi, M., & Iwamoto, N.
Affiliations
  • The Institute of Medical Science, Asahi Life Foundation (JP)
  • Eli Lilly (Japan) (JP)
ORCID
Venue
Endocrine Journal
Publisher
Japan Endocrine Society
Published
2016
Volume
63
Issue
3
Pages
263-273
ISSN
  • 0918-8959 (ISSN-L)
  • 1348-4540
DOI
10.1507/endocrj.ej15-0518
OpenAlex
W2219237166
Cited by
31
References
16
Citations by year
2026: 3 · 2025: 3 · 2024: 5 · 2022: 4 · 2021: 2 · 2020: 1 · 2018: 5 · 2017: 6 · 2016: 2
FWCI
3.77
Type
journal article
Language
en
Open access
Locations
  • Endocrine Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Eli Lilly Japan
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
dulaglutide, type 2 diabetes, Japanese patients, subgroup analysis, glycemic control, HbA1c, weight loss, biguanides, sulfonylureas, hypoglycemia, nausea, pulse rate, GLP-1 receptor agonists
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Biguanides, Combined Modality Therapy, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemia, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Middle Aged, Nausea, Recombinant Fusion Proteins, Sulfonylurea Compounds, Weight Loss, Body Mass Index, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review